The urgency behind the work is difficult to overstate. Since 2022, mpox outbreaks have emerged across multiple continents, and in 2024 a newly identified sublineage of clade I, designated Ib, triggered fresh waves of infection in several countries. The World Health Organization declared the ongoing outbreak a Public Health Emergency of International Concern on August 14, 2024, and its surveillance data recorded 52,845 confirmed cases and 215 deaths among confirmed cases globally between January and December 2025 alone. What makes clade I particularly alarming is its epidemiological profile. Transmission is no longer confined to sexual contact; confirmed household spread through close contact threatens pediatric populations, and in the current Democratic Republic of the Congo outbreak, children under 15 account for roughly 70 percent of confirmed cases and a staggering 88 percent of documented fatalities.

Clade I is also clinically distinct from clade II. Comparative studies have associated it with increased virulence, higher mortality, and more severe disease outcomes, demanding closer clinical oversight and earlier therapeutic escalation. This combination of enhanced transmissibility and heightened severity means that rapid clade discrimination is not merely a technical convenience. It is a fundamental requirement for real-time genomic surveillance, precise containment protocols, and rigorous epidemiological inquiry. PCR remains the WHO-endorsed reference assay for mpox detection, but its dependence on expensive thermal cycling equipment and its comparatively long turnaround time leave a critical gap at the point of care, particularly in resource-limited settings where clade I circulates most actively.

The new assay builds on the CRISPR/Cas12a system, an adaptive immune mechanism first identified in bacteria and archaea and now widely repurposed for viral pathogen detection. Cas12a possesses a distinctive property called trans-cleavage: once its guide RNA directs it to a matching DNA target, the enzyme promiscuously shreds nearby single-stranded DNA molecules. By flooding the reaction with single-stranded DNA reporters bearing a fluorescent tag and a quencher, researchers can convert the presence of a single target molecule into an explosive burst of fluorescence. Because Cas12a alone cannot amplify scarce templates, the system is typically paired with a pre-amplification step, and RPA has emerged as a favorite partner. Operating at just 37 to 42 degrees Celsius, RPA achieves exponential amplification within minutes using recombinase enzymes rather than heat-driven denaturation, making it an ideal match for field-deployable diagnostics.

The central engineering challenge in such combined systems is incompatibility. Premixing amplification reagents with CRISPR components in a single homogeneous reaction can actually degrade sensitivity, because premature activation of Cas12a during amplification may consume newly generated amplicons or the target templates themselves, throttling the amplification reaction before it reaches its full potential. The research team circumvented this problem with an elegantly simple physical solution: a compartmentalized tube sleeve consisting of an ordinary 1.5 milliliter microcentrifuge tube with the RPA mixture at its base, and an inverted, capless PCR tube nested inside it, held in place by surface tension and containing the preconfigured CRISPR/Cas12a detection mixture. During the 20-minute amplification at 39 degrees Celsius, the two reactions remain fully separated. A brief centrifugation then releases the CRISPR mixture into the amplified RPA reaction without ever opening the tube, minimizing both cross-contamination and aerosol exposure while allowing a further 20-minute incubation at 37 degrees Celsius to generate the fluorescent signal.

Optimization of the assay was methodical and thorough. The team produced its own LbCas12a protein in bacterial expression cells, achieving a purification purity of 96.98 percent as confirmed by thin-layer scanning, and validated its trans-cleavage activity with established positive and negative controls. Two candidate crRNAs, the guide RNAs that steer Cas12a to its target, were designed against clade I-specific conserved regions identified by comparative analysis of global MPXV genomes, and one, crRNA-I-2, produced markedly stronger fluorescence and was selected for further work. Titration experiments then pinned down the reaction cocktail: 187.5 nanomolar Cas12a protein, 25 nanomolar crRNA, and 1 micromolar single-stranded reporter, concentrations chosen to balance peak signal intensity against reagent cost. Among three RPA primer pairs, RPA-3-F/R showed the highest amplification efficiency, and a temperature gradient across 37, 39, and 42 degrees Celsius established 39 degrees as optimal.

The analytical performance figures are impressive for such a low-tech platform. Under optimized conditions, preliminary screening detected plasmid targets down to 43.7 copies per microliter, and a rigorous probit regression analysis across 20 replicates at each of five concentrations near the detection limit placed the 95 percent limit of detection at 27.16 copies per microliter, with a 95 percent confidence interval of 23.06 to 35.24 copies per microliter. All 20 replicates were positive at 43.70 copies per microliter, while detection fell to 15 of 20 at 21.85 copies and 6 of 20 at 10.93 copies, and vanished entirely below that. Specificity testing against a panel that included clade II plasmids, monkey B virus, cowpox virus, vaccinia virus, and varicella-zoster virus yielded robust fluorescence exclusively for clade I, with no cross-reactivity whatsoever. Repeatability was similarly strong, with intra-assay coefficients of variation ranging from 1.032 to 8.509 percent and inter-assay coefficients spanning 2.279 to 8.483 percent across three independent runs on different days, and negative controls remained negative throughout.

Notably, the assay retained meaningful sensitivity even without any incubator at all. At room temperature, 25 degrees Celsius, the platform reliably detected targets at 437 copies per microliter, though signal strength attenuated at lower concentrations. While this ambient-temperature performance does not match the optimized thermostated conditions, the researchers emphasize that it confirms the assay remains viable in field settings where heating devices are simply not an option. The visual readout itself is deliberately accessible: results are documented with a handheld blue-light transilluminator or even a smartphone camera, and green-channel pixel intensities extracted with image analysis software provide an objective, quantifiable measure that removes subjectivity from result interpretation.

Head-to-head evaluation against qPCR in simulated clinical samples provided perhaps the most compelling evidence of the assay’s practical value. The team spiked recombinant plasmid into total DNA extracted from Vero cells and human embryonic kidney 293T cells, generating a panel of 32 simulated samples including negative controls. Using a pixel-value threshold of 40 to distinguish signal from background, the RPA-CRISPR/Cas12a assay detected 10 of 14 spiked samples in both the Vero cell and 293T cell DNA backgrounds. Standard qPCR, run in parallel with a Ct cutoff of 35 and a requirement for a typical sigmoidal amplification curve, managed only 7 of 14 in the Vero background and 8 of 14 in the 293T background. The researchers attribute the undetected samples in both methods to target concentrations genuinely below each assay’s analytical detection limit rather than random false negatives or instability, but the outcome demonstrates that the low-equipment platform actually outperformed the laboratory-bound reference method on low-copy samples within the simulated matrices.

The authors are candid about the limitations that remain before this assay can reach clinics and field stations. crRNA design is constrained by restrictive protospacer adjacent motif requirements and by the remarkably high sequence homology, 96.8 percent, between clades I and II, though alternative Cas systems such as Cas13 and Cas14 could relax these constraints in future iterations. More significantly, the analytical evaluation relied primarily on recombinant plasmids, and while simulated samples with cellular DNA backgrounds offered a preliminary reality check, they cannot fully reproduce viral particle lysis, extraction efficiency, or the complexities of genuine clinical matrices. Validation with authentic clinical specimens or pseudovirus-based samples was not possible owing to biosafety requirements and the unavailability of clade I clinical material, and the researchers acknowledge that such evaluation will be essential. Even so, the assay fills a specific niche within an integrated diagnostic strategy: a universal mpox test would first confirm infection, after which this clade I-specific assay could stratify risk, guide clinical escalation, and sharpen surveillance of the lineage now driving the world’s most dangerous mpox outbreaks. With a 40-minute workflow, a visual readout, and no need for sophisticated equipment, it represents a practical step toward decentralized detection precisely where it is needed most.

Subject of Research: Development of a rapid one-pot RPA-CRISPR/Cas12a assay with visual readout for clade I-specific detection of monkeypox virus

Article Title: One‐Pot RPA‐CRISPR/Cas12a Assay With Visual Readout for the Ultra‐Specific Detection of Monkeypox Virus Clade I

Article References: Li, B., Liu, L., Jin, K., Huang, Z., Zhang, T., Gao, R., Chen, H., Niu, L., Fan, C., Zhang, H., Huang, P., & Wang, H. (2026). One‐Pot RPA ‐ CRISPR /Cas12a Assay With Visual Readout for the Ultra‐Specific Detection of Monkeypox Virus Clade I. Microbial Biotechnology, 19(9), Article e70437. https://doi.org/10.1111/1751-7915.70437

Image Credits: AI Generated

DOI: 10.1111/1751-7915.70437

Keywords: mpox, monkeypox virus, CRISPR/Cas12a, recombinase polymerase amplification, clade I, point-of-care diagnostics, isothermal amplification, crRNA, outbreak surveillance, limit of detection, visual readout, qPCR